
Please try another search
For the six months ended 31 December 2021, Starpharma Holdings Limited revenues increased 57% to A$2M. Net loss decreased 19% to A$8.4M. Revenues reflect Revenue from contracts with customers increase from A$486K to A$1.8M. Lower net loss reflects Research and development expense - Balan decrease of 9% to A$9.9M (expense), Corporate, administration and finance decrease of 33% to A$1.7M (expense).
Period Ending: | Dec 31, 2021 | Jun 30, 2021 | Dec 31, 2020 | Jun 30, 2020 |
---|---|---|---|---|
Total Revenue | 2.04 | 2.19 | 1.3 | 1.44 |
Gross Profit | 1.13 | 1.68 | 1.01 | 1.2 |
Operating Income | -8.45 | -9.3 | -10.43 | -8.81 |
Net Income | -8.45 | -9.3 | -10.43 | -8.81 |
Period Ending: | Dec 31, 2021 | Jun 30, 2021 | Dec 31, 2020 | Jun 30, 2020 |
---|---|---|---|---|
Total Assets | 67.32 | 73.24 | 77.98 | 39.08 |
Total Liabilities | 12.24 | 10.94 | 8.23 | 7.75 |
Total Equity | 55.08 | 62.3 | 69.75 | 31.33 |
Period Ending: | Dec 31, 2021 | Jun 30, 2021 | Dec 31, 2020 | Jun 30, 2020 |
---|---|---|---|---|
Period Length: | 6 Months | 12 Months | 6 Months | 12 Months |
Cash From Operating Activities | -11.24 | -14.81 | -5.37 | -10.78 |
Cash From Investing Activities | -0.19 | -0.25 | -0.11 | -0.12 |
Cash From Financing Activities | 2.03 | 46.3 | 46.66 | -0.58 |
Net Change in Cash | -9.25 | 30.45 | 40.22 | -11.2 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review